Altman Peter 4
4 · BioCardia, Inc. · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
BioCardia (BCDA) CEO Peter Altman Buys 5,700 Shares
What Happened Peter Altman, President, CEO and a director of BioCardia, purchased 5,700 shares of BCDA in an open-market transaction on 2026-05-18. The filing reports a weighted-average price of $0.92 per share for a total cost of $5,244. The filing characterizes this as a purchase (code P), which is a direct buy of common stock.
Key Details
- Transaction date: 2026-05-18 (filed the same day)
- Shares acquired: 5,700; weighted-average price reported: $0.92; total value reported: $5,244
- Footnote: trades were executed in multiple lots at prices ranging from $0.89 to $1.02; the $0.92 figure is the weighted average (the filer offers to provide per-trade details on request)
- Shares owned after transaction: not specified in the provided filing
- Filing timeliness: filed on the same date as the reported transaction (no late filing flag)
Context Open-market purchases by executives are often watched by investors as a signal of confidence, but note this is a relatively small ($~5.2k) purchase in dollar terms. The multi-trade execution and disclosed price range mean the reported price is an average; specific lot-level details can be requested from the filer or SEC staff per the footnote.
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-05-18$0.92/sh+5,700$5,244→ 291,566 total
Footnotes (1)
- [F1]This transaction was executed in multiple trades ranging from $0.89 to $1.02 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.